Aberrant STAT3 activation was detected in over 60% of NSCLC patients [33], which plays oncogenic roles in cell survival, stemness, metastasis, angiogenesis, drug resistance, and immune evasion [6, 8]. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.